Neur gabalin Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Mothers Pharmaceutical Co., Ltd.
MFDS item code 202003709 · Approved 2020.05.21
This product's status changed to Expired on 2025.05.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunct treatment for partial seizures in patients with epilepsy. Additionally, it helps alleviate symptoms of fibromyalgia. Overall, it contributes to pain relief and seizure control, thereby improving the quality of life for patients.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability in each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability in each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability in each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a Starting dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if there are signs of depression or mood changes during treatment, you should consult a healthcare professional immediately. Patients with hypersensitivity to this drug or with certain genetic metabolic disorders should not take it. Patients with diabetes may need to adjust their blood sugar control medications due to weight gain. If symptoms of angioedema occur, stop taking this medication immediately, and elderly patients should be cautious of injury risks due to dizziness or drowsiness. There may be blurred vision or changes in eyesight, so notify a healthcare provider if unusual symptoms occur. Abruptly stopping this medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety; therefore, it should be stopped gradually under medical supervision. Due to the risk of drug abuse, patients with a history of substance abuse should be especially cautious. Patients with impaired renal function may need a dosage adjustment. Patients with heart disease require caution when taking this medication. Since it has central nervous system depressant effects, the risk of respiratory depression may increase when taken with opioid analgesics. Dizziness and drowsiness are common, so be careful when driving or operating machinery. In the early stages of pregnancy, it may pose risks to the fetus; therefore, pregnant women should avoid taking this medication, and women of childbearing age should use effective contraception. During breastfeeding, this medication may be transmitted in breast milk, so consider stopping breastfeeding or discontinuing the medication. In cases of overdose, symptoms such as altered consciousness, drowsiness, and depression may occur, and treatment such as dialysis may be necessary if needed. Keep this medication out of the reach of children and do not transfer it to another container for safety. If unusual symptoms such as skin rash, fever, or respiratory distress occur during treatment, stop taking this medication immediately and inform a healthcare professional.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependency, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, reduced appetite, hypoglycemia, confusion, disorientation, irritability, feeling of well-being, reduced libido, depersonalization, sexual hypersensitivity, restlessness, agitation, mood swings, emotional blunting, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, disinhibition, flat affect, dizziness, drowsiness, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory reduction, sedation, hypersomnia, cognitive impairment, nystagmus, speech disorders, myoclonus, reflex reduction, abnormal movement, psychomotor agitation, positional vertigo, sensory hyperreactivity, burning sensation, action tremors, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field deficit, photophobia, dry eyes, ocular swelling, reduced vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, change in depth perception during vibration, strabismus, brightness of vision, vertigo, auditory hyperreactivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal bloating, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory reduction, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical cramps, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination problems, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling drunk, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), mood disorders, drowsiness, confusion, agitation, restlessness, seizures
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air or moisture. It is recommended to keep it at room temperature between 15 to 30 degrees Celsius.
Hard capsule with a light yellow upper part and a white lower part containing white powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 25mg
Hard capsule · Prescription medication
Mothers Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.